1Bergami A, Bemaseoni R, Caccia S, et al. Phannaeokinetics of isosorbide dinitrate in healthy volunteers alter 24-hour intravenous infusion.J Clin Pharmacol, 1997, 37: 828-833.
2Schaumann W. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. Int J Clin Pharmacol Ther Toxicol. 1989,27 : 445-453.
3Parker JA. Organic nitrates: new formulations and their clinical advantages. Am J Cardiol, 1996, 77: C38-CA0.
4Takehana K, Belier GA, Ruiz M, et al. Assessment of residual coronary stenoses using ^99m Tc-N-NOET vasodilator stress imaging to evaluate coronary flow reserve early after coronary reperfusion in a canine model of subendocardial infarction. J Nud Med, 2001,42:1388-1394.
5Abshagen U, Betzien G, Endele R, et al. Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate.Eur J Clin Pharmacol, 1981, 20: 269-275.
6Lambert CR, Grady T, Hashimi W, et al. Hemodynamic and angiographic comparison of intravenous nitroglycerin and nicardipine mainly in subjects without coronary artery disease. Am J Cardiol,1993, 71: 420-423.
10Hunt SA,Abraham WT,Chin MH,et al.ACC/AHA 2005 Guideline update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article[J].Journal of the American College of Cardiology,2005,46:1116-1143.
